---
title: "Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295819977.md"
description: "Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis"
datetime: "2026-08-13T15:26:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295819977.md)
  - [en](https://longbridge.com/en/news/295819977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295819977.md)
generator: "portal-rs"
---

# Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis


### Related Stocks

- [QNTM.US](https://longbridge.com/en/quote/QNTM.US.md)

## Related News & Research

- [Quantum BioPharma wins FDA clearance for Lucid-MS Phase 2 trial](https://longbridge.com/en/news/298731576.md)
- [Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement](https://longbridge.com/en/news/298348186.md)
- [India’s National Stock Exchange seeks $46 billion valuation in IPO](https://longbridge.com/en/news/298703061.md)
- [IMUX: Pivotal phase III data for vidofludimus calcium in relapsing MS expected by year-end, targeting NDA in 2025](https://longbridge.com/en/news/298495158.md)
- [India's NSE eyes Sep 21-week listing after regulator clears IPO, sources say](https://longbridge.com/en/news/298101548.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**